Aytu Biopharma (AYTU) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to 12.99%.
- Aytu Biopharma's EBIT Margin fell 25400.0% to 12.99% in Q4 2025 from the same period last year, while for Dec 2025 it was 13.85%, marking a year-over-year decrease of 23200.0%. This contributed to the annual value of 11.79% for FY2025, which is 84500.0% down from last year.
- Latest data reveals that Aytu Biopharma reported EBIT Margin of 12.99% as of Q4 2025, which was down 25400.0% from 10.83% recorded in Q3 2025.
- Aytu Biopharma's EBIT Margin's 5-year high stood at 16.78% during Q4 2023, with a 5-year trough of 220.76% in Q1 2022.
- In the last 5 years, Aytu Biopharma's EBIT Margin had a median value of 16.3% in 2025 and averaged 45.83%.
- In the last 5 years, Aytu Biopharma's EBIT Margin crashed by -1315900bps in 2021 and then skyrocketed by 1831100bps in 2023.
- Over the past 5 years, Aytu Biopharma's EBIT Margin (Quarter) stood at 48.84% in 2021, then surged by 46bps to 26.13% in 2022, then soared by 164bps to 16.78% in 2023, then plummeted by -162bps to 10.45% in 2024, then decreased by -24bps to 12.99% in 2025.
- Its last three reported values are 12.99% in Q4 2025, 10.83% for Q3 2025, and 50.37% during Q2 2025.